{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:41:52Z","timestamp":1792806112120,"version":"4.5.0"},"reference-count":49,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Genomic analysis in neurooncology has underscored the importance of understanding the patterns of survival in different molecular subtypes within gliomas and their responses to treatment. In particular, diffuse gliomas are now principally characterized by their mutation status (IDH1 and 1p\/19q codeletion), yet there remains a paucity of information regarding the prognostic value of molecular markers and extent of resection (EOR) on survival. Furthermore, given the modern emphasis on molecular rather than histological diagnosis, it is important to examine the effect of maximal resection on survival in all gliomas with 1p\/q19 codeletions, as these will now be classified as oligodendrogliomas under the new WHO guidelines.<\/jats:p>\n                    <jats:p>The objectives of the present study were twofold: 1) to assess the association between EOR and survival for patients with oligodendrogliomas in the National Cancer Database (NCDB), which includes information on mutation status, and 2) to demonstrate the same effect for all patients with 1p\/19q codeleted gliomas in the NCDB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>The NCDB was queried for all cases of oligodendroglioma between 2004 and 2014, with follow-up dates through 2016. The authors found 2514 cases of histologically confirmed oligodendrogliomas for the final analysis of the effect of EOR on survival. Upon further query, 1067 1p\/19q-codeleted tumors were identified in the NCDB. Patients who received subtotal resection (STR) or gross-total resection (GTR) were compared to those who received no tumor debulking surgery. Univariable and multivariable analyses of both overall survival and cause-specific survival were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>EOR was associated with increased overall survival for both histologically confirmed oligodendrogliomas and all 1p\/19q-codeleted\u2013defined tumors (p &lt; 0.001 and p = 0.002, respectively). Tumor grade, location, and size covaried predictably with EOR. When evaluating tumors by each classification system for predictors of overall survival, facility setting, age, comorbidity index, grade, location, chemotherapy, and radiation therapy were all shown to be significantly associated with overall survival. STR and GTR were independent predictors of improved survival in historically classified oligodendrogliomas (HR 0.83, p = 0.18; HR 0.69, p = 0.01, respectively) and in 1p\/19q-codeleted tumors (HR 0.49, p &lt; 0.01; HR 0.43, p &lt; 0.01, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>By using the NCDB, the authors have demonstrated a side-by-side comparison of the survival benefits of greater EOR in 1p\/19q-codeleted gliomas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3171\/2020.2.jns192767","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T03:37:42Z","timestamp":1588909062000},"page":"1357-1367","source":"Crossref","is-referenced-by-count":39,"title":["Extent of resection, molecular signature, and survival in 1p19q-codeleted gliomas"],"prefix":"10.3171","volume":"134","author":[{"given":"Andrew L. A.","family":"Garton","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, NewYork-Presbyterian Hospital\/Weill Cornell Medical Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor J.","family":"Kinslow","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Vagelos College of Physicians and Surgeons, NewYork-Presbyterian Hospital\/Columbia University Irving Medical Center, New York, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali I.","family":"Rae","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Oregon Health & Sciences University, Portland, Oregon;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Neurology, Vagelos College of Physicians and Surgeons, NewYork-Presbyterian Hospital\/Columbia University Irving Medical Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C.","family":"Pannullo","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, NewYork-Presbyterian Hospital\/Weill Cornell Medical Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv S.","family":"Magge","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, NewYork-Presbyterian Hospital\/Weill Cornell Medical Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Ramakrishna","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, NewYork-Presbyterian Hospital\/Weill Cornell Medical Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy M.","family":"McKhann","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Vagelos College of Physicians and Surgeons, NewYork-Presbyterian Hospital\/Columbia University Irving Medical Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Sisti","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Vagelos College of Physicians and Surgeons, NewYork-Presbyterian Hospital\/Columbia University Irving Medical Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey N.","family":"Bruce","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Vagelos College of Physicians and Surgeons, NewYork-Presbyterian Hospital\/Columbia University Irving Medical Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Canoll","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, NewYork-Presbyterian Hospital\/Columbia University Irving Medical Center;"},{"name":"Departments of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, NewYork-Presbyterian Hospital\/Columbia University Irving Medical Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon K.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Vagelos College of Physicians and Surgeons, NewYork-Presbyterian Hospital\/Columbia University Irving Medical Center, New York, New York;"},{"name":"Department of Epidemiology, Mailman School of Public Health, and Department of Medicine, Vagelos College of Physicians and Surgeons, NewYork-Presbyterian Hospital\/Columbia University Irving Medical Center, New York, New York; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Sonabend","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony J. C.","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Vagelos College of Physicians and Surgeons, NewYork-Presbyterian Hospital\/Columbia University Irving Medical Center, New York, New York;"},{"name":"Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, NewYork-Presbyterian Hospital\/Columbia University Irving Medical Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"issue":"26","key":"b1","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","article-title":"Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas","volume":"372","author":"Brat\n \nDJ","year":"2015","unstructured":"Brat\n \nDJ\n\n, \n\nVerhaak\n \nRG\n\n, \n\nAldape\n \nKD\n\n, \n\n\n \nComprehensive, integrative genomic analysis of diffuse lower-grade gliomas\n. \nN Engl J Med\n. \n2015\n;\n372\n(\n26\n):\n2481\n\u2013\n2498\n.\n10.1056\/NEJMoa140212126061751"},{"issue":"4","key":"b2","series-title":"Am J Pathol","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.2353\/ajpath.2009.080958","article-title":"IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas","volume":"174","author":"Watanabe\n \nT","year":"2009","unstructured":"Watanabe\n \nT\n\n, \n\nNobusawa\n \nS\n\n, \n\nKleihues\n \nP\n\n, \n\nOhgaki\n \nH\n\n\n. \nIDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas\n. \nAm J Pathol\n. \n2009\n;\n174\n(\n4\n):\n1149\n\u2013\n1153\n.\n1924664710.2353\/ajpath.2009.080958"},{"issue":"13","key":"b3","series-title":"Clin Cancer Res","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.1158\/1078-0432.CCR-10-3194","article-title":"Molecular markers in low-grade gliomas: predictive or prognostic?","volume":"17","author":"Hartmann\n \nC","year":"2011","unstructured":"Hartmann\n \nC\n\n, \n\nHentschel\n \nB\n\n, \n\nTatagiba\n \nM\n\n, \n\n\n \nMolecular markers in low-grade gliomas: predictive or prognostic?\n \nClin Cancer Res\n. \n2011\n;\n17\n(\n13\n):\n4588\n\u2013\n4599\n.\n10.1158\/1078-0432.CCR-10-3194"},{"issue":"3","key":"b4","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s11060-014-1593-0","article-title":"1p\/19q-driven prognostic molecular classification for high-grade oligodendroglial tumors","volume":"120","author":"Jiang\n \nH","year":"2014","unstructured":"Jiang\n \nH\n\n, \n\nZhang\n \nZ\n\n, \n\nRen\n \nX\n\n, \n\n\n \n1p\/19q-driven prognostic molecular classification for high-grade oligodendroglial tumors\n. \nJ Neurooncol\n. \n2014\n;\n120\n(\n3\n):\n607\n\u2013\n614\n.\n2515150710.1007\/s11060-014-1593-0"},{"key":"b5","series-title":"Seizure","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.seizure.2019.05.018","article-title":"Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control","volume":"69","author":"Feyissa\n \nAM","year":"2019","unstructured":"Feyissa\n \nAM\n\n, \n\nWorrell\n \nGA\n\n, \n\nTatum\n \nWO\n\n, \n\n\n \nPotential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control\n. \nSeizure\n. \n2019\n;\n69\n:\n283\n\u2013\n289\n.\n3114178510.1016\/j.seizure.2019.05.018"},{"issue":"2","key":"b6","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11060-015-1906-y","article-title":"Prognostic significance of relative 1p\/19q codeletion in oligodendroglial tumors","volume":"125","author":"Chamberlain\n \nMC","year":"2015","unstructured":"Chamberlain\n \nMC\n\n, \n\nBorn\n \nD\n\n\n. \nPrognostic significance of relative 1p\/19q codeletion in oligodendroglial tumors\n. \nJ Neurooncol\n. \n2015\n;\n125\n(\n2\n):\n249\n\u2013\n251\n.\n10.1007\/s11060-015-1906-y26341371"},{"issue":"1","key":"b7","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11060-018-03027-5","article-title":"Eighty percent survival rate at 15 years for 1p\/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade","volume":"141","author":"Iwadate\n \nY","year":"2019","unstructured":"Iwadate\n \nY\n\n, \n\nMatsutani\n \nT\n\n, \n\nHara\n \nA\n\n, \n\n\n \nEighty percent survival rate at 15 years for 1p\/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade\n. \nJ Neurooncol\n. \n2019\n;\n141\n(\n1\n):\n205\n\u2013\n211\n.\n10.1007\/s11060-018-03027-530565028"},{"issue":"20","key":"b8","series-title":"Cancer Res","doi-asserted-by":"publisher","first-page":"9852","DOI":"10.1158\/0008-5472.CAN-06-1796","article-title":"A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma","volume":"66","author":"Jenkins\n \nRB","year":"2006","unstructured":"Jenkins\n \nRB\n\n, \n\nBlair\n \nH\n\n, \n\nBallman\n \nKV\n\n, \n\n\n \nA t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma\n. \nCancer Res\n. \n2006\n;\n66\n(\n20\n):\n9852\n\u2013\n9861\n.\n10.1158\/0008-5472.CAN-06-1796"},{"issue":"1","key":"b9","series-title":"Sci Rep","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/s41598-017-19014-1","article-title":"Recurrence patterns after maximal surgical resection and postoperative radiotherapy in anaplastic gliomas according to the new 2016 WHO classification","volume":"8","author":"Im\n \nJH","year":"2018","unstructured":"Im\n \nJH\n\n, \n\nHong\n \nJB\n\n, \n\nKim\n \nSH\n\n, \n\n\n \nRecurrence patterns after maximal surgical resection and postoperative radiotherapy in anaplastic gliomas according to the new 2016 WHO classification\n. \nSci Rep\n. \n2018\n;\n8\n(\n1\n):\n777\n.\n10.1038\/s41598-017-19014-1"},{"issue":"10","key":"b10","series-title":"Carcinogenesis","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1093\/carcin\/bgz102","article-title":"Systematically characterize the clinical and biological significances of 1p19q genes in 1p\/19q non-codeletion glioma","volume":"40","author":"Chai\n \nR-C","year":"2019","unstructured":"Chai\n \nR-C\n\n, \n\nZhang\n \nK-N\n\n, \n\nChang\n \nY-Z\n\n, \n\n\n \nSystematically characterize the clinical and biological significances of 1p19q genes in 1p\/19q non-codeletion glioma\n. \nCarcinogenesis\n. \n2019\n;\n40\n(\n10\n):\n1229\n\u2013\n1239\n.\n10.1093\/carcin\/bgz10231157866"},{"issue":"23","key":"b11","series-title":"Neurology","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1212\/WNL.0b013e3181e1cf3a","article-title":"All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2","volume":"74","author":"Labussi\u00e8re\n \nM","year":"2010","unstructured":"Labussi\u00e8re\n \nM\n\n, \n\nIdbaih\n \nA\n\n, \n\nWang\n \nX-W\n\n, \n\n\n \nAll the 1p19q codeleted gliomas are mutated on IDH1 or IDH2\n. \nNeurology\n. \n2010\n;\n74\n(\n23\n):\n1886\n\u2013\n1890\n.\n10.1212\/WNL.0b013e3181e1cf3a"},{"issue":"3","key":"b12","series-title":"Can J Neurol Sci","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1017\/cjn.2016.420","article-title":"Treatment outcomes in 1p19q co-deleted\/partially deleted gliomas","volume":"44","author":"McNamara\n \nMG","year":"2017","unstructured":"McNamara\n \nMG\n\n, \n\nJiang\n \nH\n\n, \n\nLim-Fat\n \nMJ\n\n, \n\n\n \nTreatment outcomes in 1p19q co-deleted\/partially deleted gliomas\n. \nCan J Neurol Sci\n. \n2017\n;\n44\n(\n3\n):\n288\n\u2013\n294\n.\n10.1017\/cjn.2016.42028488951"},{"issue":"8","key":"b13","series-title":"Clin Oncol (R Coll Radiol)","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.clon.2015.04.008","article-title":"FISHing tips: what every clinician should know about 1p19q analysis in gliomas using fluorescence in situ hybridisation","volume":"27","author":"Pinkham\n \nMB","year":"2015","unstructured":"Pinkham\n \nMB\n\n, \n\nTelford\n \nN\n\n, \n\nWhitfield\n \nGA\n\n, \n\n\n \nFISHing tips: what every clinician should know about 1p19q analysis in gliomas using fluorescence in situ hybridisation\n. \nClin Oncol (R Coll Radiol)\n. \n2015\n;\n27\n(\n8\n):\n445\n\u2013\n453\n.\n10.1016\/j.clon.2015.04.00825971646"},{"issue":"2","key":"b14","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s11060-019-03096-0","article-title":"Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p\/19q status in diffuse low- and high-grade gliomas","volume":"142","author":"Zhou\n \nH","year":"2019","unstructured":"Zhou\n \nH\n\n, \n\nChang\n \nK\n\n, \n\nBai\n \nHX\n\n, \n\n\n \nMachine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p\/19q status in diffuse low- and high-grade gliomas\n. \nJ Neurooncol\n. \n2019\n;\n142\n(\n2\n):\n299\n\u2013\n307\n.\n10.1007\/s11060-019-03096-030661193"},{"issue":"1","key":"b15","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1023\/A:1005715405413","article-title":"Low grade gliomas: functional mapping resection strategies, extent of resection, and outcome","volume":"34","author":"Berger\n \nMS","year":"1997","unstructured":"Berger\n \nMS\n\n, \n\nRostomily\n \nRC\n\n\n. \nLow grade gliomas: functional mapping resection strategies, extent of resection, and outcome\n. \nJ Neurooncol\n. \n1997\n;\n34\n(\n1\n):\n85\n\u2013\n101\n.\n921005510.1023\/A:1005715405413"},{"issue":"3","key":"b16","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s11060-019-03261-5","article-title":"Extent of resection and survival for oligodendroglioma: a U.S. population-based study","volume":"144","author":"Kinslow\n \nCJ","year":"2019","unstructured":"Kinslow\n \nCJ\n\n, \n\nGarton\n \nALA\n\n, \n\nRae\n \nAI\n\n, \n\n\n \nExtent of resection and survival for oligodendroglioma: a U.S. population-based study\n. \nJ Neurooncol\n. \n2019\n;\n144\n(\n3\n):\n591\n\u2013\n601\n.\n10.1007\/s11060-019-03261-5"},{"issue":"4","key":"b17","series-title":"Neurosurgery","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1227\/01.NEU.0000325729.41085.73","article-title":"Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas","volume":"63","author":"McGirt\n \nMJ","year":"2008","unstructured":"McGirt\n \nMJ\n\n, \n\nChaichana\n \nKL\n\n, \n\nAttenello\n \nFJ\n\n, \n\n\n \nExtent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas\n. \nNeurosurgery\n. \n2008\n;\n63\n(\n4\n):\n700\n\u2013\n708\n.\n1898188010.1227\/01.NEU.0000325729.41085.73"},{"issue":"8","key":"b18","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1200\/JCO.2007.13.9337","article-title":"Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas","volume":"26","author":"Smith\n \nJS","year":"2008","unstructured":"Smith\n \nJS\n\n, \n\nChang\n \nEF\n\n, \n\nLamborn\n \nKR\n\n, \n\n\n \nRole of extent of resection in the long-term outcome of low-grade hemispheric gliomas\n. \nJ Clin Oncol\n. \n2008\n;\n26\n(\n8\n):\n1338\n\u2013\n1345\n.\n10.1200\/JCO.2007.13.933718323558"},{"issue":"2","key":"b19","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3171\/2013.10.JNS13368","article-title":"The impact of extent of resection on malignant transformation of pure oligodendrogliomas","volume":"120","author":"Snyder\n \nLA","year":"2014","unstructured":"Snyder\n \nLA\n\n, \n\nWolf\n \nAB\n\n, \n\nOppenlander\n \nME\n\n, \n\n\n \nThe impact of extent of resection on malignant transformation of pure oligodendrogliomas\n. \nJ Neurosurg\n. \n2014\n;\n120\n(\n2\n):\n309\n\u2013\n314\n.\n10.3171\/2013.10.JNS1336824313617"},{"issue":"suppl 3","key":"b20","series-title":"Ann Oncol","doi-asserted-by":"publisher","first-page":"iii93","DOI":"10.1093\/annonc\/mdu050","article-title":"High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Stupp\n \nR","year":"2014","unstructured":"Stupp\n \nR\n\n, \n\nBrada\n \nM\n\n, \n\nvan den Bent\n \nMJ\n\n, \n\n\n \nHigh-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\n. \nAnn Oncol\n. \n2014\n;\n25\n(\nsuppl 3\n):\niii93\n\u2013\niii101\n.\n2478245410.1093\/annonc\/mdu050"},{"issue":"5","key":"b21","series-title":"CNS Oncol","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2217\/cns.15.26","article-title":"The role of surgery in grade II\/III oligodendroglial tumors","volume":"4","author":"Thon\n \nN","year":"2015","unstructured":"Thon\n \nN\n\n, \n\nKreth\n \nF-W\n\n, \n\nTonn\n \nJ-C\n\n\n. \nThe role of surgery in grade II\/III oligodendroglial tumors\n. \nCNS Oncol\n. \n2015\n;\n4\n(\n5\n):\n317\n\u2013\n323\n.\n2647813310.2217\/cns.15.26"},{"issue":"1","key":"b22","series-title":"Neuro Oncol","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/neuonc\/not159","article-title":"IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection","volume":"16","author":"Beiko\n \nJ","year":"2014","unstructured":"Beiko\n \nJ\n\n, \n\nSuki\n \nD\n\n, \n\nHess\n \nKR\n\n, \n\n\n \nIDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection\n. \nNeuro Oncol\n. \n2014\n;\n16\n(\n1\n):\n81\n\u2013\n91\n.\n10.1093\/neuonc\/not15924305719"},{"key":"b23","series-title":"J Neurosurg","article-title":"To treat or not to treat? A retrospective multicenter assessment of survival in patients with IDH-mutant low-grade glioma based on adjuvant treatment [published online July 19, 2019]","author":"Pa\u013ea\n \nA","unstructured":"Pa\u013ea\n \nA\n\n, \n\nCoburger\n \nJ\n\n, \n\nScherer\n \nM\n\n, \n\n\n \nTo treat or not to treat? A retrospective multicenter assessment of survival in patients with IDH-mutant low-grade glioma based on adjuvant treatment [published online July 19, 2019]\n. \nJ Neurosurg\n. \ndoi:10.3171\/2019.4.JNS183395"},{"issue":"7","key":"b24","series-title":"AJNR Am J Neuroradiol","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3174\/ajnr.A6102","article-title":"Extent of surgical resection in lower-grade gliomas: differential impact based on molecular subtype","volume":"40","author":"Patel\n \nSH","year":"2019","unstructured":"Patel\n \nSH\n\n, \n\nBansal\n \nAG\n\n, \n\nYoung\n \nEB\n\n, \n\n\n \nExtent of surgical resection in lower-grade gliomas: differential impact based on molecular subtype\n. \nAJNR Am J Neuroradiol\n. \n2019\n;\n40\n(\n7\n):\n1149\n\u2013\n1155\n.\n3124886010.3174\/ajnr.A6102"},{"issue":"1","key":"b25","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s11060-018-03030-w","article-title":"Surgical management of lower-grade glioma in the spotlight of the 2016 WHO classification system","volume":"141","author":"Delev\n \nD","year":"2019","unstructured":"Delev\n \nD\n\n, \n\nHeiland\n \nDH\n\n, \n\nFranco\n \nP\n\n, \n\n\n \nSurgical management of lower-grade glioma in the spotlight of the 2016 WHO classification system\n. \nJ Neurooncol\n. \n2019\n;\n141\n(\n1\n):\n223\n\u2013\n233\n.\n10.1007\/s11060-018-03030-w30467813"},{"issue":"2","key":"b26","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s11060-018-03044-4","article-title":"Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60","volume":"141","author":"Morshed\n \nRA","year":"2019","unstructured":"Morshed\n \nRA\n\n, \n\nHan\n \nSJ\n\n, \n\nHervey-Jumper\n \nSL\n\n, \n\n\n \nMolecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60\n. \nJ Neurooncol\n. \n2019\n;\n141\n(\n2\n):\n383\n\u2013\n391\n.\n10.1007\/s11060-018-03044-430498891"},{"issue":"4","key":"b27","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.3171\/2016.11.JNS161974","article-title":"Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis","volume":"128","author":"Alattar\n \nAA","year":"2018","unstructured":"Alattar\n \nAA\n\n, \n\nBrandel\n \nMG\n\n, \n\nHirshman\n \nBR\n\n, \n\n\n \nOligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis\n. \nJ Neurosurg\n. \n2018\n;\n128\n(\n4\n):\n1076\n\u2013\n1083\n.\n2849805910.3171\/2016.11.JNS161974"},{"issue":"1","key":"b28","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11060-017-2430-z","article-title":"Survival trends of oligodendroglial tumor patients and associated clinical practice patterns: a SEER-based analysis","volume":"133","author":"Brandel\n \nMG","year":"2017","unstructured":"Brandel\n \nMG\n\n, \n\nAlattar\n \nAA\n\n, \n\nHirshman\n \nBR\n\n, \n\n\n \nSurvival trends of oligodendroglial tumor patients and associated clinical practice patterns: a SEER-based analysis\n. \nJ Neurooncol\n. \n2017\n;\n133\n(\n1\n):\n173\n\u2013\n181\n.\n2843977710.1007\/s11060-017-2430-z"},{"issue":"6","key":"b29","series-title":"Acta Neuropathol","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"Louis\n \nDN","year":"2016","unstructured":"Louis\n \nDN\n\n, \n\nPerry\n \nA\n\n, \n\nReifenberger\n \nG\n\n, \n\n\n \nThe 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary\n. \nActa Neuropathol\n. \n2016\n;\n131\n(\n6\n):\n803\n\u2013\n820\n.\n2715793110.1007\/s00401-016-1545-1"},{"issue":"3","key":"b30","series-title":"Ann Surg Oncol","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","article-title":"The National Cancer Data Base: a powerful initiative to improve cancer care in the United States","volume":"15","author":"Bilimoria\n \nKY","year":"2008","unstructured":"Bilimoria\n \nKY\n\n, \n\nStewart\n \nAK\n\n, \n\nWinchester\n \nDP\n\n, \n\nKo\n \nCY\n\n\n. \nThe National Cancer Data Base: a powerful initiative to improve cancer care in the United States\n. \nAnn Surg Oncol\n. \n2008\n;\n15\n(\n3\n):\n683\n\u2013\n690\n.\n10.1245\/s10434-007-9747-318183467"},{"issue":"3","key":"b31","series-title":"Neuro Oncol","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/neuonc\/1.3.205","article-title":"Centralized databases available for describing primary brain tumor incidence, survival, and treatment: Central Brain Tumor Registry of the United States; Surveillance, Epidemiology, and End Results; and National Cancer Data Base","volume":"1","author":"Davis\n \nFG","year":"1999","unstructured":"Davis\n \nFG\n\n, \n\nMcCarthy\n \nBJ\n\n, \n\nBerger\n \nMS\n\n\n. \nCentralized databases available for describing primary brain tumor incidence, survival, and treatment: Central Brain Tumor Registry of the United States; Surveillance, Epidemiology, and End Results; and National Cancer Data Base\n. \nNeuro Oncol\n. \n1999\n;\n1\n(\n3\n):\n205\n\u2013\n211\n.\n1155438910.1093\/neuonc\/1.3.205"},{"issue":"suppl 4","key":"b32","series-title":"Neuro Oncol","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012","volume":"17","author":"Ostrom\n \nQT","year":"2015","unstructured":"Ostrom\n \nQT\n\n, \n\nGittleman\n \nH\n\n, \n\nFulop\n \nJ\n\n, \n\n\n \nCBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012\n. \nNeuro Oncol\n. \n2015\n;\n17\n(\nsuppl 4\n):\niv1\n\u2013\niv62\n.\n10.1093\/neuonc\/nov18926511214"},{"key":"b33","article-title":"Revised for 2013. American College of Surgeons","author":"Facility Oncology Registry Data Standards (FORDS)","unstructured":"Facility Oncology Registry Data Standards (FORDS)\n\n\n. \nRevised for 2013. American College of Surgeons\n. \nhttps:\/\/www.facs.org\/\u223c\/media\/files\/quality%20programs\/cancer\/coc\/fords\/fords%20manual%202013.ashx\n. Accessed March 12, 2020\n."},{"key":"b34","series-title":"World Neurosurg","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.wneu.2017.03.103","article-title":"Management and survival patterns of patients with gliomatosis cerebri: a SEER-based analysis","volume":"103","author":"Carroll\n \nKT","year":"2017","unstructured":"Carroll\n \nKT\n\n, \n\nHirshman\n \nB\n\n, \n\nAli\n \nMA\n\n, \n\n\n \nManagement and survival patterns of patients with gliomatosis cerebri: a SEER-based analysis\n. \nWorld Neurosurg\n. \n2017\n;\n103\n:\n186\n\u2013\n193\n.\n10.1016\/j.wneu.2017.03.10328366748"},{"issue":"1","key":"b35","series-title":"Neurooncol Pract","first-page":"29","article-title":"Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: a SEER-based analysis","volume":"3","author":"Dong\n \nX","year":"2016","unstructured":"Dong\n \nX\n\n, \n\nNoorbakhsh\n \nA\n\n, \n\nHirshman\n \nBR\n\n, \n\n\n \nSurvival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: a SEER-based analysis\n. \nNeurooncol Pract\n. \n2016\n;\n3\n(\n1\n):\n29\n\u2013\n38\n."},{"issue":"3","key":"b36","series-title":"Neurosurgery","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1227\/01.neu.0000431477.02408.5e","article-title":"Survival and prognostic factors of anaplastic gliomas","volume":"73","author":"Nu\u00f1o\n \nM","year":"2013","unstructured":"Nu\u00f1o\n \nM\n\n, \n\nBirch\n \nK\n\n, \n\nMukherjee\n \nD\n\n, \n\n\n \nSurvival and prognostic factors of anaplastic gliomas\n. \nNeurosurgery\n. \n2013\n;\n73\n(\n3\n):\n458\n\u2013\n465\n.\n10.1227\/01.neu.0000431477.02408.5e23719055"},{"key":"b37","series-title":"World Neurosurg","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.wneu.2017.03.140","article-title":"Effect of gross total resection in World Health Organization Grade II astrocytomas: SEER-based survival analysis","volume":"103","author":"Schupper\n \nAJ","year":"2017","unstructured":"Schupper\n \nAJ\n\n, \n\nHirshman\n \nBR\n\n, \n\nCarroll\n \nKT\n\n, \n\n\n \nEffect of gross total resection in World Health Organization Grade II astrocytomas: SEER-based survival analysis\n. \nWorld Neurosurg\n. \n2017\n;\n103\n:\n741\n\u2013\n747\n.\n10.1016\/j.wneu.2017.03.14028419878"},{"key":"b38","series-title":"Breast","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.breast.2016.10.007","article-title":"More than just the median: calculating survival times for patients with HER2 positive, metastatic breast cancer using data from recent randomised trials","volume":"31","author":"Vasista\n \nA","year":"2017","unstructured":"Vasista\n \nA\n\n, \n\nStockler\n \nMR\n\n, \n\nWest\n \nT\n\n, \n\n\n \nMore than just the median: calculating survival times for patients with HER2 positive, metastatic breast cancer using data from recent randomised trials\n. \nBreast\n. \n2017\n;\n31\n:\n99\n\u2013\n104\n.\n2782920210.1016\/j.breast.2016.10.007"},{"issue":"8","key":"b39","series-title":"Clin Cancer Res","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1158\/1078-0432.CCR-18-3101","article-title":"The misclassification of diffuse gliomas: rates and outcomes","volume":"25","author":"Iorgulescu\n \nJB","year":"2019","unstructured":"Iorgulescu\n \nJB\n\n, \n\nTorre\n \nM\n\n, \n\nHarary\n \nM\n\n, \n\n\n \nThe misclassification of diffuse gliomas: rates and outcomes\n. \nClin Cancer Res\n. \n2019\n;\n25\n(\n8\n):\n2656\n\u2013\n2663\n.\n3063534010.1158\/1078-0432.CCR-18-3101"},{"key":"b40","series-title":"World Neurosurg","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.wneu.2017.04.035","article-title":"Prognostic implications of extent of resection in glioblastoma: analysis from a large database","volume":"103","author":"Trifiletti\n \nDM","year":"2017","unstructured":"Trifiletti\n \nDM\n\n, \n\nAlonso\n \nC\n\n, \n\nGrover\n \nS\n\n, \n\n\n \nPrognostic implications of extent of resection in glioblastoma: analysis from a large database\n. \nWorld Neurosurg\n. \n2017\n;\n103\n:\n330\n\u2013\n340\n.\n2842798610.1016\/j.wneu.2017.04.035"},{"key":"b41","series-title":"Clin Neurol Neurosurg","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.clineuro.2019.04.027","article-title":"Impact of 1p\/19q codeletion status on extent of resection in WHO grade II glioma: insights from a national cancer registry","volume":"182","author":"Lu\n \nVM","year":"2019","unstructured":"Lu\n \nVM\n\n, \n\nAlvi\n \nMA\n\n, \n\nBydon\n \nM\n\n, \n\n\n \nImpact of 1p\/19q codeletion status on extent of resection in WHO grade II glioma: insights from a national cancer registry\n. \nClin Neurol Neurosurg\n. \n2019\n;\n182\n:\n32\n\u2013\n36\n.\n10.1016\/j.clineuro.2019.04.027"},{"issue":"3","key":"b42","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11060-016-2201-2","article-title":"Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1\/2 mutation without the 1p\/19q co-deletion","volume":"129","author":"Kawaguchi\n \nT","year":"2016","unstructured":"Kawaguchi\n \nT\n\n, \n\nSonoda\n \nY\n\n, \n\nShibahara\n \nI\n\n, \n\n\n \nImpact of gross total resection in patients with WHO grade III glioma harboring the IDH 1\/2 mutation without the 1p\/19q co-deletion\n. \nJ Neurooncol\n. \n2016\n;\n129\n(\n3\n):\n505\n\u2013\n514\n.\n2740115410.1007\/s11060-016-2201-2"},{"key":"b43","series-title":"J Clin Neurosci","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jocn.2017.10.087","article-title":"Impact of academic facility type and volume on post-surgical outcomes following diagnosis of glioblastoma","volume":"47","author":"Hauser\n \nA","year":"2018","unstructured":"Hauser\n \nA\n\n, \n\nDutta\n \nSW\n\n, \n\nShowalter\n \nTN\n\n, \n\n\n \nImpact of academic facility type and volume on post-surgical outcomes following diagnosis of glioblastoma\n. \nJ Clin Neurosci\n. \n2018\n;\n47\n:\n103\n\u2013\n110\n.\n10.1016\/j.jocn.2017.10.08729113851"},{"key":"b44","series-title":"J Clin Neurosci","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jocn.2016.12.003","article-title":"Racial disparities in anaplastic oligodendroglioma: an analysis on 1643 patients","volume":"37","author":"Shin\n \nJY","year":"2017","unstructured":"Shin\n \nJY\n\n, \n\nYoon\n \nJK\n\n, \n\nDiaz\n \nAZ\n\n\n. \nRacial disparities in anaplastic oligodendroglioma: an analysis on 1643 patients\n. \nJ Clin Neurosci\n. \n2017\n;\n37\n:\n34\n\u2013\n39\n.\n2802473310.1016\/j.jocn.2016.12.003"},{"issue":"2","key":"b45","series-title":"Int J Epidemiol","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/ije\/29.2.197","article-title":"Cancer prevalence estimates based on tumour registry data in the Surveillance, Epidemiology, and End Results (SEER) Program","volume":"29","author":"Merrill\n \nRM","year":"2000","unstructured":"Merrill\n \nRM\n\n, \n\nCapocaccia\n \nR\n\n, \n\nFeuer\n \nEJ\n\n, \n\nMariotto\n \nA\n\n\n. \nCancer prevalence estimates based on tumour registry data in the Surveillance, Epidemiology, and End Results (SEER) Program\n. \nInt J Epidemiol\n. \n2000\n;\n29\n(\n2\n):\n197\n\u2013\n207\n.\n10.1093\/ije\/29.2.19710817114"},{"issue":"9","key":"b46","series-title":"Med Care","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1097\/01.MLR.0000086827.00805.B5","article-title":"Can cancer registry data be used to study cancer treatment?","volume":"41","author":"Warren\n \nJL","year":"2003","unstructured":"Warren\n \nJL\n\n, \n\nHarlan\n \nLC\n\n\n. \nCan cancer registry data be used to study cancer treatment?\n \nMed Care\n. \n2003\n;\n41\n(\n9\n):\n1003\n\u2013\n1005\n.\n10.1097\/01.MLR.0000086827.00805.B5"},{"issue":"7514","key":"b47","series-title":"Nature","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/nature13387","article-title":"A vaccine targeting mutant IDH1 induces antitumour immunity","volume":"512","author":"Schumacher\n \nT","year":"2014","unstructured":"Schumacher\n \nT\n\n, \n\nBunse\n \nL\n\n, \n\nPusch\n \nS\n\n, \n\n\n \nA vaccine targeting mutant IDH1 induces antitumour immunity\n. \nNature\n. \n2014\n;\n512\n(\n7514\n):\n324\n\u2013\n327\n.\n2504304810.1038\/nature13387"},{"issue":"6","key":"b48","series-title":"Acta Neuropathol","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00401-015-1424-1","article-title":"Oligodendroglioma: pathology, molecular mechanisms and markers","volume":"129","author":"Wesseling\n \nP","year":"2015","unstructured":"Wesseling\n \nP\n\n, \n\nvan den Bent\n \nM\n\n, \n\nPerry\n \nA\n\n\n. \nOligodendroglioma: pathology, molecular mechanisms and markers\n. \nActa Neuropathol\n. \n2015\n;\n129\n(\n6\n):\n809\n\u2013\n827\n.\n2594388510.1007\/s00401-015-1424-1"},{"issue":"5","key":"b49","series-title":"Clin Cancer Res","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1158\/1078-0432.CCR-19-3257","article-title":"Misclassification of diffuse gliomas\u2014letter","volume":"26","author":"Kinslow\n \nCJ","year":"2020","unstructured":"Kinslow\n \nCJ\n\n, \n\nCanoll\n \nP\n\n, \n\nCheng\n \nSK\n\n, \n\nWang\n \nTJC\n\n\n. \nMisclassification of diffuse gliomas\u2014letter\n. \nClin Cancer Res\n\n. \n2020\n;\n26\n(\n5\n):\n1198\n.\n3212292910.1158\/1078-0432.CCR-19-3257"}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/134\/5\/article-p1357.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/134\/5\/article-p1357.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/134\/5\/article-p1357.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:52:07Z","timestamp":1792803127000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/134\/5\/article-p1357.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":49,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.3171\/2020.2.jns192767","relation":{},"ISSN":["0022-3085","1933-0693"],"issn-type":[{"value":"0022-3085","type":"print"},{"value":"1933-0693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}